Physician
Hematology
Dr. Daniel D. Karp, MD
|
|
Give Review
Daniel Karp is an expert in the field of Hematology. He researched medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. He received awards:"Super Doctor". Daniel Karp is a published doctor. He has 58 papers published. The most current publication "Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design."
Publications
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced ...
- Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer:...
- Vitamin E and the risk of prostate Cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Molecular analysis of non-small cell lung Cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
- Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small Cell lung carcinoma.
- Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and ...
- Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung Cancer with or without brain metastases.
- Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung Cancer.
- Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, local...
- The changing face of phase 1 Cancer clinical trials: new challenges in study requirements.
- Effect of selenium and vitamin E on risk of prostate Cancer and other Cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung Cancer.
- Gene promoter methylation in plasma and sputum increases with lung Cancer risk.
- Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
- Nonsmall-cell lung Cancer: chemoprevention studies.
- A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal Cancer.
- Down-regulation and antiproliferative role of C/EBPalpha in lung Cancer.
- Progression of Basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele.
- Adrenal corticosteroids as antiemetics during cancer chemotherapy.
- Eastern cooperative group trial of interferon gamma in metastatic Melanoma: an innovative study design.
- Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II).
- Role of chemotherapy in the multidisciplinary approach to advanced head and neck Cancer: potentials and problems.
- Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature.
- Disturbing central nervous system complications following combination chemotherapy and prophylactic whole-brain irradiation in patients with small cell lung Cancer.
- Local excision of Rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin.
- Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck Cancer. A long-term follow-up report.
- FDG imaging of a pulmonary artery sarcoma.
- Lingual necrosis as the initial symptom of small Cell carcinoma.
- The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal Cell tumors.
- N2 lung Cancer: outcome in patients with false-negative computed tomographic scans of the chest.
- A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial Gliomas--an Eastern Cooperative Oncology Group ...
- An association between the risk of Cancer and mutations in the HRAS1 minisatellite locus.
- Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced so...
- Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic Melanoma: an Eastern Cooperative Oncology Group Study (E1686).
- Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy.
- Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
- Phase II trial of docetaxel (Taxotere) in patients with adenoCarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Easter...
- Lung Cancer detection in the 21st century: potential contributions and challenges of emerging technologies.
- Adoptive immunotherapy for nonsmall Cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above.
- Lung Cancer chemoprevention and management of carcinoma in situ.
- A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck Cancer.
- A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall Cell lung carcinoma: an Eastern Cooperative...
- Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung Cancer: The Eastern Cooperative Oncology Group Results.
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung Cancer.
- Activity of docetaxel in platinum-treated non-small-cell lung Cancer: results of a phase II multicenter trial.
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
- Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall Cell lung carcinoma.
- Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung Cancer brain metastasis patients.
- Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung Cancer.
- A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous Cell carcinoma of the head and neck.
- Prevention of second primary tumors with isotretinoin in squamous-Cell carcinoma of the head and neck.
- Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung Cancer previously treated with platinum-containi...
- Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-Cell lung ...
- Evaluating quality in clinical Cancer research: the M.D. Anderson Cancer Center experience.
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory Cancers.
Schools
Duke University School Of Medicine
Dart Hitchcock Med Center
Dana Farber Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Dartmouth-Hitchcock Medical Center -
Duke University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1295753671 | |
| NPPES Provider LastName | KARP | |
| NPPES Provider FirstName | DANIEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 243.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 11.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295753671 |
| Last Name Of The Provider | KARP |
| First Name Of The Provider | DANIEL |
| View All |
Similar Doctors
|
|
Dr. Roberto N. Miranda, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Jay B. Shah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Debasish P. Tripathy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohamed T. Elghetany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Qaiser Bashir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle M. Hebert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Cyprus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jacqueline S. Hart, MD |
|
|
Dr. Apostolia M. Tsimberidou, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Christopher B. Benton, MD |
|
|
Dr. Syed K. Azeemuddin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanza S. Abbas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Korbling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditi Shastri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aditya Shetty, MD |